目的研究拟探讨瘦素(leptin)对长链脂酰辅酶A家族成员长链脂酰辅A合成酶5(acyl-CoA synthetase long chain family member 5,ACSL5)的调控作用及机制,并探究其对乳腺癌细胞迁移和侵袭的影响。方法免疫荧光实验检测瘦素受体的表达;划痕...目的研究拟探讨瘦素(leptin)对长链脂酰辅酶A家族成员长链脂酰辅A合成酶5(acyl-CoA synthetase long chain family member 5,ACSL5)的调控作用及机制,并探究其对乳腺癌细胞迁移和侵袭的影响。方法免疫荧光实验检测瘦素受体的表达;划痕愈合实验和Transwell实验检测细胞迁移、侵袭能力;采用PCR芯片数据分析瘦素下游靶基因,生物信息学方法分析ACSL5在乳腺癌中的表达、与患者分期及预后关系;RT-qPCR检测不同浓度瘦素处理后ACSL5的表达;慢病毒转染构建过表达ACSL5稳转株;Western blot检测上皮-间质转化(epithelial-mesenchymal transition,EMT)相关蛋白表达及AMPK-α、p-AMPK-α的表达。结果瘦素促进MCF-7细胞体外迁移和侵袭及EMT;ACSL5是瘦素下游靶基因,在乳腺癌中显著低表达且与患者预后相关;瘦素通过其受体OBR下调ACSL5的表达;瘦素激活AMPK通路下调ACSL5促进乳腺癌MCF-7细胞迁移和侵袭及EMT。结论瘦素可能通过激活AMPK通路下调ACSL5,增强乳腺癌细胞的迁移和侵袭能力并促进其EMT进程,从而促进乳腺癌恶性进展。展开更多
Objective:Mitochondrial fatty acid oxidation is a metabolic pathway whose dysregulation is recognized as a critical factor in various cancers,because it sustains cancer cell survival,proliferation,and metastasis.The a...Objective:Mitochondrial fatty acid oxidation is a metabolic pathway whose dysregulation is recognized as a critical factor in various cancers,because it sustains cancer cell survival,proliferation,and metastasis.The acyl-Co A synthetase long-chain(ACSL)family is known to activate long-chain fatty acids,yet the specific role of ACSL3 in breast cancer has not been determined.Methods:We assessed the prognostic value of ACSL3 in breast cancer by using data from tumor samples.Gain-of-function and lossof-function assays were also conducted to determine the roles and downstream regulatory mechanisms of ACSL3 in vitro and in vivo.Results:ACSL3 expression was notably downregulated in breast cancer tissues compared with normal tissues,and this phenotype correlated with improved survival outcomes.Functional experiments revealed that ACSL3 knockdown in breast cancer cells promoted cell proliferation,migration,and epithelial±mesenchymal transition.Mechanistically,ACSL3 was found to inhibitβ-oxidation and the formation of associated byproducts,thereby suppressing malignant behavior in breast cancer.Importantly,ACSL3 was found to interact with YES proto-oncogene 1,a member of the Src family of tyrosine kinases,and to suppress its activation through phosphorylation at Tyr419.The decrease in activated YES1 consequently inhibited YAP1 nuclear colocalization and transcriptional complex formation,and the expression of its downstream genes in breast cancer cell nuclei.Conclusions:ACSL3 suppresses breast cancer progression by impeding lipid metabolism reprogramming,and inhibiting malignant behaviors through phospho-YES1 mediated inhibition of YAP1 and its downstream pathways.These findings suggest that ACSL3 may serve as a potential biomarker and target for comprehensive therapeutic strategies for breast cancer.展开更多
文摘目的研究拟探讨瘦素(leptin)对长链脂酰辅酶A家族成员长链脂酰辅A合成酶5(acyl-CoA synthetase long chain family member 5,ACSL5)的调控作用及机制,并探究其对乳腺癌细胞迁移和侵袭的影响。方法免疫荧光实验检测瘦素受体的表达;划痕愈合实验和Transwell实验检测细胞迁移、侵袭能力;采用PCR芯片数据分析瘦素下游靶基因,生物信息学方法分析ACSL5在乳腺癌中的表达、与患者分期及预后关系;RT-qPCR检测不同浓度瘦素处理后ACSL5的表达;慢病毒转染构建过表达ACSL5稳转株;Western blot检测上皮-间质转化(epithelial-mesenchymal transition,EMT)相关蛋白表达及AMPK-α、p-AMPK-α的表达。结果瘦素促进MCF-7细胞体外迁移和侵袭及EMT;ACSL5是瘦素下游靶基因,在乳腺癌中显著低表达且与患者预后相关;瘦素通过其受体OBR下调ACSL5的表达;瘦素激活AMPK通路下调ACSL5促进乳腺癌MCF-7细胞迁移和侵袭及EMT。结论瘦素可能通过激活AMPK通路下调ACSL5,增强乳腺癌细胞的迁移和侵袭能力并促进其EMT进程,从而促进乳腺癌恶性进展。
基金supported by the National Natural Science Foundation of China(Grant No.82203786)the Natural Science Foundation of Liaoning Province of China(Grant No.2022-YGJC-68 and Grant No.2023-BS-105)the Chinese Young Breast Experts Research Project(Grant No.CYBER-2021-A02 and Grant No.CYBER-2022-001)。
文摘Objective:Mitochondrial fatty acid oxidation is a metabolic pathway whose dysregulation is recognized as a critical factor in various cancers,because it sustains cancer cell survival,proliferation,and metastasis.The acyl-Co A synthetase long-chain(ACSL)family is known to activate long-chain fatty acids,yet the specific role of ACSL3 in breast cancer has not been determined.Methods:We assessed the prognostic value of ACSL3 in breast cancer by using data from tumor samples.Gain-of-function and lossof-function assays were also conducted to determine the roles and downstream regulatory mechanisms of ACSL3 in vitro and in vivo.Results:ACSL3 expression was notably downregulated in breast cancer tissues compared with normal tissues,and this phenotype correlated with improved survival outcomes.Functional experiments revealed that ACSL3 knockdown in breast cancer cells promoted cell proliferation,migration,and epithelial±mesenchymal transition.Mechanistically,ACSL3 was found to inhibitβ-oxidation and the formation of associated byproducts,thereby suppressing malignant behavior in breast cancer.Importantly,ACSL3 was found to interact with YES proto-oncogene 1,a member of the Src family of tyrosine kinases,and to suppress its activation through phosphorylation at Tyr419.The decrease in activated YES1 consequently inhibited YAP1 nuclear colocalization and transcriptional complex formation,and the expression of its downstream genes in breast cancer cell nuclei.Conclusions:ACSL3 suppresses breast cancer progression by impeding lipid metabolism reprogramming,and inhibiting malignant behaviors through phospho-YES1 mediated inhibition of YAP1 and its downstream pathways.These findings suggest that ACSL3 may serve as a potential biomarker and target for comprehensive therapeutic strategies for breast cancer.
